Skip to main content
OpenTrials
Completed

NCT Number: NCT01303692

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent

Completed

Looking for future studies?

Notify Me

Key information

Conditions

GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

50 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Research Site, Seongnam-si, Gyeonggi-do, South Korea

Loading trial locations.

About this study

MC MD

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Korean prostate cancer over 50 years old with pathological confirmation
  • Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting.
  • Patients measured bone density level before starting to receive hormone therapies above.

Exclusion criteria

  • Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0.
  • Patients who are hard to be analysed by attach to other bone disease.
  • Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.

Treatment and study plan

Primary outcomes

  1. comparison of bone density before and after hormone therapy

    Time frame: 1 year

  2. comparison of bone density between GnRH agonist alone vs. CAB group

    Time frame: 1 year

Secondary outcomes

  1. correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value

    Time frame: 1 year

  2. correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value before and after hormone therapy

    Time frame: 1 year

  3. 1year comparison of FRAX score before and after hormonal therapy

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Feb 25, 2011
Registry last updated
Jan 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.